Key Takeaways:
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) plans to initiate a Phase 2 trial for its single-dose Lyme disease prophylactic, TNX-4800, in the first half of 2027, offering a potential alternative to multi-dose vaccines in development.
"As a monoclonal antibody, we believe TNX-4800 offers significant advantages over vaccines in development," said Seth Lederman, MD, Chief Executive Officer of Tonix Pharmaceuticals. "Lyme disease vaccines that elicit antibodies to OspA currently in development take more than six months to offer protection and require complex immunization schedules."
The decision follows a Phase 1 study of 44 healthy adults where TNX-4800 was well-tolerated and demonstrated a half-life of 62-69 days, sustaining protective blood levels for at least four months. The proposed Phase 2 trial will use a single 350 mg subcutaneous dose and will measure efficacy in preventing Lyme disease at four and six months.
With nearly 476,000 Americans diagnosed annually, a single-dose prophylactic offering rapid protection could capture a significant share of a market where the leading vaccine candidate from Pfizer and Valneva requires four doses. The success of TNX-4800 could be a major value driver for Tonix, which in-licensed the drug from UMass Chan Medical School in 2025.
TNX-4800 is a long-acting human monoclonal antibody that provides passive immunity by directly supplying neutralizing antibodies. This differs from a vaccine, which stimulates the body's immune system to create its own antibodies. The antibody targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that causes 99.9% of Lyme disease cases in the U.S. The mechanism works by killing the bacteria in the tick's mid-gut after it ingests the blood of a treated person, preventing transmission.
The Phase 1 study showed TNX-4800 was rapidly absorbed, with measurable serum concentrations at the first sampling time of two days. Most adverse events were mild or moderate. Based on these results, the company selected a fixed 350 mg dose for the Phase 2 study, which will enroll adolescents and adults aged 16 to 65 in Lyme-endemic areas of the U.S. Tonix expects to have the investigational product ready for clinical testing in early 2027. The company's cash runway for these developments was not disclosed.
Currently, there are no FDA-approved prophylactics for Lyme disease. An earlier vaccine, Lymerix, was withdrawn from the market in 2002. The most advanced candidate is a four-dose vaccine from Pfizer and Valneva, which has shown approximately 70% efficacy in Phase 3 trials. Tonix believes TNX-4800's single-dose administration and rapid onset of protection could offer a meaningful improvement for the 87 million people in the U.S. at high risk for the disease.
This article is for informational purposes only and does not constitute investment advice.
